Inovio Pharma (INO) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.28 +3.23%
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: +75.9%
Financial Fact:
License fee and milestone revenue: 2.33M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Inovio Pharma (NASDAQ: INO) reported Q2 EPS of ($0.09), $0.04 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $5.3 million versus the consensus estimate of $5.52 million.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- ’Not your father’s Sandisk’: Rosenblatt starts coverage at Buy
- Goldman: 'Our key conclusion is that AI is likely to be credit-positive for banks', 'Rearming Our Overweight Stance on Banks'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
